secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001615219-25-000107
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharma CEO David J. Arthur resigns; CFO Mark J. Rosenblum named acting CEO
--------------------------------------------------------------------------------

- David J. Arthur resigned as CEO effective Aug 17, 2025; not due to any disagreement with the company.
- Mark J. Rosenblum appointed acting CEO, continuing as EVP and CFO; no new employment agreement.
- Consulting agreement with Arthur terminated immediately upon resignation.
- Rosenblum has served as EVP Finance/CFO since Sep 2019; previously CFO of Advaxis, Inc.
- Company working to finalize previously announced merger with Decoy Therapeutics Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000107/0001615219-25-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000107/flks-20250817.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer